Floatz logo

59 assets in Neuroendocrine Neoplasm

Therapeutic assets addressing Neuroendocrine Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Immunoglobulin G1 [143-Aspartic Acid,236-Glutamic Acid], Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Hbm4003 Heavy Chain V-D-J Region) Fusion Protein With Immunoglobulin G1 (Human ?1-Chain C Region), Dimer
Neuroendocrine Neoplasm
Harbour BioMed (Guangzhou) Co. Ltd.P1C (39)
L-Tryptophan, 1-(2-(Fluoro-18F)Ethyl)-
Neuroendocrine Neoplasm
Barbara Ann Karmanos Cancer InstituteP1C (39)
nn3201
Neuroendocrine Neoplasm
Novelty Nobility, Inc.P1C (39)
ryz401
Neuroendocrine Neoplasm
RayzeBio, Inc.P1C (39)
Sapu003
Neuroendocrine Neoplasm
SAPU NANO (US) LLCP1C (39)
Toripalimab
Neuroendocrine Neoplasm
Harbour BioMed (Guangzhou) Co. Ltd.P1C (39)
[212pb] vmt-α-net
Neuroendocrine Neoplasm
David BushnellEarly P1C (36)
177lu-ctr-fapi
Neuroendocrine Neoplasm
Xijing HospitalN/AD (30)
crn09682
Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.P1/2NR ()
Showing 51 to 59 of 59 assets
PreviousPage 2 of 2Next